Session » Sjögren's Syndrome – Basic & Clinical Science Poster II

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2302

A Specific Molecular Profiling of Secreted Rheumatoid Factors in Sjögren’ S Disease Patients with Lymphoma

10:30AM-12:30PM: Abstract Number: 2300

Activation of Tissue-Resident T Cells in Sjögren’s Disease with Human Salivary Organoids

10:30AM-12:30PM: Abstract Number: 2293

Altered Expression of the MicroRNA Biogenesis Machinery Components Correlates with Inflammatory Parameters in Salivary Glands of Patient with Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 2305

Anti-Ku Positivity in Primary Sjögren’s Disease Is Associated with a More Systemic Active Disease

10:30AM-12:30PM: Abstract Number: 2295

Association of Early Markers in Patients with Sjögren’s Syndrome in a Diverse Academic Cohort

10:30AM-12:30PM: Abstract Number: 2289

Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study

10:30AM-12:30PM: Abstract Number: 2308

Characterization of Damage in a Primary Sjogren’s Syndrome Cohort

10:30AM-12:30PM: Abstract Number: 2299

Clinical and Serological Characteristics of Sjögren’s Disease-related Lymphocytic Interstitial Pneumonia: A Large Multicenter Study

10:30AM-12:30PM: Abstract Number: 2309

Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren’s Syndrome

10:30AM-12:30PM: Abstract Number: 2306

Deconstruction and Reconstruction of Sjögren’s Disease: AMP®-AIM Partnership

10:30AM-12:30PM: Abstract Number: 2307

Deep Spatial Profiling Unveils Dominant Double Negative B Cells in Severe Forms of Sjögren’s Syndrome

10:30AM-12:30PM: Abstract Number: 2304

Differential Diagnosis of Sjogren’s vs Non-Sjogren’s Dry Eye

10:30AM-12:30PM: Abstract Number: 2298

Fibroblast-driven Ttek Activation May Drive Acinar Cell Dysfunction in Sjögren’s Disease, Prior to Lymphocytic Infiltration

10:30AM-12:30PM: Abstract Number: 2292

Fibroblasts with High Expression of CD74 Promote Lymphocytes Infiltration in Salivary Gland in Sjӧgren’s Disease

10:30AM-12:30PM: Abstract Number: 2287

Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study

10:30AM-12:30PM: Abstract Number: 2288

Interferon Gamma Signaling Is Associated with Development of Extraglandular Manifestations in Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 2297

Mortality and Its Predictor Variables in Patients with Sjögren Disease: Data from SjögrenSER-Pros Prospective Registry

10:30AM-12:30PM: Abstract Number: 2294

Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study

10:30AM-12:30PM: Abstract Number: 2310

Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease

10:30AM-12:30PM: Abstract Number: 2301

The Added Value of anti-Ro52 Antibody Titer in the Diagnosis of Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 2291

The Relationship of the ESSDAI to Health-Related Quality of Life in People Living with Sjogren’s Disease

10:30AM-12:30PM: Abstract Number: 2296

The Value of Ultrasound to Follow Glandular Disease in Sjogren’s Disease Patients

10:30AM-12:30PM: Abstract Number: 2303

Type I Interferon Signature Drives Phenotypic Clusters of Sjögren’s Disease and Can Predict Systemic Evolution Among the “B-cell Active with Low Symptoms” Subgroup

10:30AM-12:30PM: Abstract Number: 2290

Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].